Northern Institute for Cancer Research, Newcastle University, UK.
Cancer Treat Rev. 2012 Apr;38(2):89-100. doi: 10.1016/j.ctrv.2011.04.015. Epub 2011 Jun 28.
Homologous recombination (HR) is a process by which DNA double strand breaks are repaired through the alignment of homologous sequences of DNA. Interest continues to increase in HR pathway function due to the development of new therapeutic agents which selectively exploit DNA damage repair pathways. Currently the most promising of these new agents are inhibitors of poly(ADP ribose) polymerase (PARP). The response of cancers known to be deficient in HR, due to BRCA1 or 2 mutations has been demonstrated, and a wider use of PARP inhibitors in cancers with mutations of other HR pathway genes has been suggested. With ongoing clinical studies into the use of PARP inhibitors, further understanding of the HR pathway, to allow patient selection by cancer biology, is now essential. Numerous studies have investigated individual aberrations of genes involved in the HR pathway. Here we collate this evidence to give an overview of the role of the HR pathway in human cancer.
同源重组（HR）是一种通过同源 DNA 序列的对齐来修复 DNA 双链断裂的过程。由于开发了选择性利用 DNA 损伤修复途径的新治疗药物，HR 途径功能的兴趣不断增加。目前，这些新药物中最有前途的是聚（ADP 核糖）聚合酶（PARP）抑制剂。由于 BRCA1 或 2 突变导致 HR 缺陷的癌症的反应已经得到证实，并且建议在其他 HR 途径基因突变的癌症中更广泛地使用 PARP 抑制剂。随着 PARP 抑制剂使用的临床研究不断进行，为了通过癌症生物学进行患者选择，现在必须更好地了解 HR 途径。许多研究已经研究了参与 HR 途径的基因的个体异常。在这里，我们汇集这些证据，概述 HR 途径在人类癌症中的作用。
